Skip to main content
Erschienen in: Tumor Biology 4/2013

01.08.2013 | Research Article

RETRACTED ARTICLE: XRCC3 T241M polymorphism is associated risk of hepatocellular carcinoma in the Chinese

verfasst von: Chibo Liu, Haibao Wang

Erschienen in: Tumor Biology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The X-ray repair cross-complementing group 3 (XRCC3) gene has been suggested to play an important role in the pathogenesis of hepatocellular carcinoma (HCC). However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of XRCC3 Thr241Met variant with HCC. The published literature from PubMed, Chinese National Knowledge Infrastructure, and Wan Fang data was retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed or random effects model. A total of five studies (1,531 HCC cancer cases and 1,952 controls) for XRCC3 Thr241Met variant were included in the meta-analysis. The meta-analysis showed that XRCC3 Thr241Met variant was associated with HCC risk under homogeneous codominant model (OR = 3.99, 95 % CI = 1.74–9.13) and recessive model (OR = 5.22, 95 % CI = 3.65–7.48), but not under heterogeneous codominant model (OR = 1.18, 95 % CI = 0.68–2.05) and dominant model (OR = 1.37, 95 % CI = 0.73–2.57). Subgroup analysis by ethnicity suggested that XRCC3 Thr241Met variant was associated with HCC risk in Chinese population, but not in Pakistani population. The present meta-analysis supported the positive association of XRCC3 Thr241Met variant with HCC in the Chinese. Further large-scale studies with the consideration for gene–gene/gene–environment interactions should be conducted to investigate the association.
Literatur
1.
Zurück zum Zitat Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med. 2007;120:194–202.CrossRefPubMed Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med. 2007;120:194–202.CrossRefPubMed
2.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
3.
Zurück zum Zitat Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst. 2000;92:874–97.CrossRefPubMed Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst. 2000;92:874–97.CrossRefPubMed
4.
Zurück zum Zitat Miller MC, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicol Lett. 2001;120:269–80.CrossRefPubMed Miller MC, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicol Lett. 2001;120:269–80.CrossRefPubMed
5.
Zurück zum Zitat Zipprich J, Terry MB, Brandt-Rauf P, Freyer GA, Liao Y, Agrawal M, et al. XRCC1 polymorphisms and breast cancer risk from the New York site of the Breast Cancer Family Registry: a family-based case–control study. J Carcinog. 2010;9:4.CrossRefPubMedPubMedCentral Zipprich J, Terry MB, Brandt-Rauf P, Freyer GA, Liao Y, Agrawal M, et al. XRCC1 polymorphisms and breast cancer risk from the New York site of the Breast Cancer Family Registry: a family-based case–control study. J Carcinog. 2010;9:4.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Xu L. Association between polymorphism of DNA repair genes and hepatocellular carcinoma susceptibility: a case–control study. Master's dissertation of Fudan University; 2003. 1–42. Chinese. Xu L. Association between polymorphism of DNA repair genes and hepatocellular carcinoma susceptibility: a case–control study. Master's dissertation of Fudan University; 2003. 1–42. Chinese.
7.
Zurück zum Zitat Long XD, Ma Y, de Qu Y, Liu YG, Huang ZQ, Huang YZ, et al. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi population, China. Ann Epidemiol. 2008;18:572–8.CrossRefPubMed Long XD, Ma Y, de Qu Y, Liu YG, Huang ZQ, Huang YZ, et al. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi population, China. Ann Epidemiol. 2008;18:572–8.CrossRefPubMed
8.
Zurück zum Zitat Liu W. The relation between genetic polymorphism of DNA repair gene XRCC3, XRCC4 and susceptibility to primary hepatocellular carcinoma. Master's dissertation of Fujian Medical University. 1–56. Chinese. Liu W. The relation between genetic polymorphism of DNA repair gene XRCC3, XRCC4 and susceptibility to primary hepatocellular carcinoma. Master's dissertation of Fujian Medical University. 1–56. Chinese.
9.
Zurück zum Zitat Han X, Xing Q, Li Y, Sun J, Ji H, Huazheng P, Jun L. Study on the DNA repair genes XRCC1 and XRCC3 polymorphisms in prediction and prognosis of hepatocellular carcinoma risk. Hepatogastroenterology. 2012;59 (119): doi:10.5754/hge12096. Han X, Xing Q, Li Y, Sun J, Ji H, Huazheng P, Jun L. Study on the DNA repair genes XRCC1 and XRCC3 polymorphisms in prediction and prognosis of hepatocellular carcinoma risk. Hepatogastroenterology. 2012;59 (119): doi:10.​5754/​hge12096.
10.
Zurück zum Zitat Zeng X, Liu S, Yu H, Ji L, Li L, Huang J, et al. DNA repair capacity, DNA-strand break repair gene polymorphisms, and the incidence of hepatocellular carcinoma in southwestern Guangxi of China. DNA Cell Biol. 2012;31:1384–91.CrossRefPubMedPubMedCentral Zeng X, Liu S, Yu H, Ji L, Li L, Huang J, et al. DNA repair capacity, DNA-strand break repair gene polymorphisms, and the incidence of hepatocellular carcinoma in southwestern Guangxi of China. DNA Cell Biol. 2012;31:1384–91.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Gulnaz A, Sayyed AH, Amin F, Khan A, Aslam MA, Shaikh RS, et al. Association of XRCC1, XRCC3, and XPD genetic polymorphism with an increased risk of hepatocellular carcinoma because of the hepatitis B and C virus. Eur J Gastroenterol Hepatol. 2013;25:166–79.CrossRefPubMed Gulnaz A, Sayyed AH, Amin F, Khan A, Aslam MA, Shaikh RS, et al. Association of XRCC1, XRCC3, and XPD genetic polymorphism with an increased risk of hepatocellular carcinoma because of the hepatitis B and C virus. Eur J Gastroenterol Hepatol. 2013;25:166–79.CrossRefPubMed
12.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed
13.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
14.
Zurück zum Zitat Long XD, Ma Y, Deng ZL, Huang YZ, Wei NB. Association of the Thr241Met polymorphism of DNA repair gene XRCC3 with genetic susceptibility to AFB1-related hepatocellular carcinoma in Guangxi population. Chin J Med Genet. 2008;25:268–71. Chinese. Long XD, Ma Y, Deng ZL, Huang YZ, Wei NB. Association of the Thr241Met polymorphism of DNA repair gene XRCC3 with genetic susceptibility to AFB1-related hepatocellular carcinoma in Guangxi population. Chin J Med Genet. 2008;25:268–71. Chinese.
15.
Zurück zum Zitat Xu YH, Gu LP, Sun YJ, Cheng BJ, Lu S. No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2013;34(2):865–74.CrossRefPubMed Xu YH, Gu LP, Sun YJ, Cheng BJ, Lu S. No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2013;34(2):865–74.CrossRefPubMed
16.
Zurück zum Zitat Liu L, Miao L, Ji G, Qiang F, Liu Z, Fan Z. Association between XRCC1 and XRCC3 polymorphisms and colorectal cancer risk: a meta-analysis of 23 case–control studies. Mol Biol Rep. 2012. doi:10.1007/s11033-012-2471-5. Liu L, Miao L, Ji G, Qiang F, Liu Z, Fan Z. Association between XRCC1 and XRCC3 polymorphisms and colorectal cancer risk: a meta-analysis of 23 case–control studies. Mol Biol Rep. 2012. doi:10.​1007/​s11033-012-2471-5.
17.
Zurück zum Zitat Yin QH, Liu C, Li L, Zu XY, Wang YJ. Association between the XRCC3 T241M polymorphism and head and neck cancer susceptibility: a meta-analysis of case–control studies. Asian Pac J Cancer Prev. 2012;13:5201–5.CrossRefPubMed Yin QH, Liu C, Li L, Zu XY, Wang YJ. Association between the XRCC3 T241M polymorphism and head and neck cancer susceptibility: a meta-analysis of case–control studies. Asian Pac J Cancer Prev. 2012;13:5201–5.CrossRefPubMed
18.
Zurück zum Zitat He XF, Wei W, Su J, Yang ZX, Liu Y, Zhang Y, et al. Association between the XRCC3 polymorphisms and breast cancer risk: meta-analysis based on case–control studies. Mol Biol Rep. 2012;39:5125–34.CrossRefPubMed He XF, Wei W, Su J, Yang ZX, Liu Y, Zhang Y, et al. Association between the XRCC3 polymorphisms and breast cancer risk: meta-analysis based on case–control studies. Mol Biol Rep. 2012;39:5125–34.CrossRefPubMed
19.
Zurück zum Zitat Li F, Li C, Jiang Z, Ma N, Gao X. XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis. Urology. 2011;77:511.e1–5.PubMed Li F, Li C, Jiang Z, Ma N, Gao X. XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis. Urology. 2011;77:511.e1–5.PubMed
20.
Zurück zum Zitat Fang F, Wang J, Yao L, Yu XJ, Yu L, Yu L. Relationship between XRCC3 T241M polymorphism and gastric cancer risk: a meta-analysis. Med Oncol. 2011;28:999–1003.CrossRefPubMed Fang F, Wang J, Yao L, Yu XJ, Yu L, Yu L. Relationship between XRCC3 T241M polymorphism and gastric cancer risk: a meta-analysis. Med Oncol. 2011;28:999–1003.CrossRefPubMed
Metadaten
Titel
RETRACTED ARTICLE: XRCC3 T241M polymorphism is associated risk of hepatocellular carcinoma in the Chinese
verfasst von
Chibo Liu
Haibao Wang
Publikationsdatum
01.08.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0765-4

Weitere Artikel der Ausgabe 4/2013

Tumor Biology 4/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.